FDA Targeting GDUFA Fee Scofflaws Again With Letters
This article was originally published in The Pink Sheet Daily
Executive Summary
Four warning letters this year have gone to companies that owe finished dosage form and active pharmaceutical ingredient facility fees.
You may also be interested in...
User Fee Program Six-Month Metrics
After six months under the new prescription drug, generic drug and biosimilar user fee programs, FDA has shown some progress in collecting the necessary fees and conducting sponsor meetings required under the new programs.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.